COVID-19: Vaccines and Therapeutics
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical trial three COVID-19 vaccine candidates that target better or longer-lasting immune response; increase central laboratory capacity for…
The Department of Health and Human Services in November will begin transitioning to commercial distribution an estimated 7.9 million treatment courses of the COVID-19 antiviral pill Paxlovid under an agreement with Pfizer announced.
The AHA has excellent resources to help hospital and health system teams encourage patients and people in their communities to get vaccinated against the flu, COVID-19 and RSV.
The Food and Drug Administration authorized for emergency use an updated Novavax COVID-19 vaccine for individuals aged 12 and older, providing a non-mRNA alternative to the Moderna and Pfizer vaccines.
As we move into fall and winter, we know the viruses that cause respiratory disease will usually circulate more heavily in communities. Already, the Centers for Disease Control and Prevention has said it expects this year to be similar to last year when we saw higher than normal numbers of…
In these video snippets from an AHA Advancing Health podcast series, health care leaders and clinicians from four children's hospitals share how they worked to foster COVID-19 vaccine confidence in their communities.
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug Administration authorized or approved the vaccines, Health and Human Services Secretary Xavier Becerra reminded the payer community Sept. 22, citing…
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating Americans against COVID-19, flu and RSV to prevent against severe outcomes such as hospitalization and death.
As authorized Sept. 11 by the Food and Drug Administration, the Centers for Disease Control and Prevention today recommended a single dose of the updated Moderna and Pfizer COVID-19 vaccines for Americans aged 12 and older, and one or two doses of the updated vaccines for previously vaccinated…
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list price for a new commercialized product could not exceed the retail price in comparable markets globally, HHS said.